Tags

Type your tag names separated by a space and hit enter

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion.
Respir Med Case Rep 2019; 28:100927RM

Abstract

We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma.

Authors+Show Affiliations

Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany. Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Germany.Schoen Klinik Berchtesgadener Land, Department of Pneumology, Member of the German Center for Lung Research (DZL), Schoenau am Königssee, Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany.Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Germany.Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany.Department of Pneumology, University Hospital Freiburg, Freiburg, Germany.Pulmonary Department, Mainz University Hospital, Mainz, Germany.Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. Member of the German Center for Lung Research (DZL), Germany. Schoen Klinik Berchtesgadener Land, Department of Pneumology, Member of the German Center for Lung Research (DZL), Schoenau am Königssee, Germany.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

31485410

Citation

Tello, Khodr, et al. "Anti-interleukin-5 Therapy (mepolizumab) in Life-threatening Asthma Attack: a Case-based Discussion." Respiratory Medicine Case Reports, vol. 28, 2019, p. 100927.
Tello K, Hoffmann A, Beutel B, et al. Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. Respir Med Case Rep. 2019;28:100927.
Tello, K., Hoffmann, A., Beutel, B., Greulich, T., Vogelmeier, C. F., Richter, M. J., ... Koczulla, A. R. (2019). Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. Respiratory Medicine Case Reports, 28, p. 100927. doi:10.1016/j.rmcr.2019.100927.
Tello K, et al. Anti-interleukin-5 Therapy (mepolizumab) in Life-threatening Asthma Attack: a Case-based Discussion. Respir Med Case Rep. 2019;28:100927. PubMed PMID: 31485410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. AU - Tello,Khodr, AU - Hoffmann,Andreas, AU - Beutel,Björn, AU - Greulich,Timm, AU - Vogelmeier,Claus Franz, AU - Richter,Manuel Jonas, AU - Kuhnert,Stefan, AU - Böselt,Tobias, AU - Alter,Peter, AU - Holland,Angelique, AU - Idzko,Marco, AU - Buhl,Roland, AU - Koczulla,Andreas Rembert, Y1 - 2019/08/22/ PY - 2019/07/16/received PY - 2019/08/14/revised PY - 2019/08/21/accepted PY - 2019/9/6/entrez PY - 2019/9/6/pubmed PY - 2019/9/6/medline KW - Anti-IL-5-therapy KW - Asthma KW - Eosinophilia KW - Exacerbation KW - Intensive care medicine SP - 100927 EP - 100927 JF - Respiratory medicine case reports JO - Respir Med Case Rep VL - 28 N2 - We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma. SN - 2213-0071 UR - https://www.unboundmedicine.com/medline/citation/31485410/Anti-interleukin-5_therapy_(mepolizumab)_in_life-threatening_asthma_attack:_A_case-based_discussion L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-0071(19)30218-7 DB - PRIME DP - Unbound Medicine ER -